Share

June 2020; 10 (3) Editorial

Making public and patient involvement in clinical trials more than aspirational

Holly E. Hinson, Roy H. Hamilton, David B. Matchar
First published December 4, 2019, DOI: https://doi.org/10.1212/CPJ.0000000000000786
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
37

Share

Article Information

vol. 10 no. 3 188-189
DOI: 
https://doi.org/10.1212/CPJ.0000000000000786
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • First Published December 4, 2019.

Article Versions

Copyright & Usage: 
© 2019 American Academy of Neurology

Author Disclosures

    1. Holly E. Hinson, MD, MCR,
    2. Roy H. Hamilton, MD, MS and
    3. David B. Matchar, MD
  1. Holly E. Hinson, MD, MCR,
    2. Scientific Advisory Boards:

    1. (1) Biogen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1)AAN annual meeting speaking honorarium

    Editorial Boards:

    1. 1) Neurocritical Care, Editorial Board, 2018-present 2) Current Treatment Options in Neurology, Section Editor, 2019 3) Neurology, Associate Editor for Equity, Diversity, Inclusion, and Disparities, 2019

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Medical Research Foundation of Oregon- New Investigator Award

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Roy H. Hamilton, MD, MS and
    3. Scientific Advisory Boards:

    1. 1) I am the safety monitor for two NIH-funded R21 projects and a Research Project Cooperative Agreement (U01) award. There is no overlap between the topics addressed in this manuscript and the aims of these grants. 2) I am on the Scientific Advisory Board for an NIH-funded program project award (2P01AG031720). I receive compensation for my role. There is no overlap between the topics addressed in this manuscript and the aims of the program project.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1)Cognitive and Behavioral Neurology, editorial board member, 2015 to present (2)Restorative Neurology and Neuroscience, editorial board member, 2011 to present (3) Senior editor, Neurobiology of Language, 2019 to present (4) Associate Editor for Equity, Diversity, and Inclusion, Neurology (and the Neurology family of journals), 2019 to present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I served as a consultant for Geurbet Ltd. on the development of an FDA-mandated clinical trial. I received approximately $10000 for this work over 2 years (2017-18) There is no overlap between the topics addressed in this manuscript and my role in this company. I have served as a medical consultant for Neuronix LTD from, 2014 to 2018; I received approximately $10000 for this work. there is no overlap between the topics addressed in this manuscript and my role in this company.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) NIH/NIA 5P30-AG-010124-27 Co-Investigator 7/15/97-6/30/19 2) NIH/NIDCD 1 R01 DC012780-01A1 Principal Investigator 7/01/2013 - 6/30/2019 3) NIH/NIDCD 2-R01-DC-009209-11 Co-Investigator 6/01/2014 - 5/31/2019 4) NIH/NIDCR DP5OD021352 Co-Investigator 9/19/2015 - 08/31/2020 5) NIH/NIDCD 1R01DC015359-01A1 Co-Investigator 4/01/2016 - 3/31/2021 6) University of Pennsylvania/Translational Neuroscience Initiative (TNI) Co-Investigator 7/01/2016 - 6/30/2019 7) NIH/NEI R01EY022350 Co-Investigator 9/01/2016 - 8/31/2021 8) NIH/NINDS 5P30NS045839-12 Co-Investigator 2/1/2014-1/31/2018 9) NIH/NINDS 1R01DC016800-01A1 Co-Investigator 10/1/17-9/30/22 10) Association for Frontotemporal Dementia Principal Investigator 1/01/2016 – 12/31/2016 11) Dana Foundation Principal Investigator 12/13/2012 - 4/24/2018

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. David B. Matchar, MD
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. Lundbeck Foundation, Education Advisor, $5000. Not related to MS.

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. UptoDate, American College of Physicians, Section on asymptomatic carotid disease.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Singapore National Medical Research Council, Enhancing Primary Care in Singapore, PI, $2M.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Oregon Health Sciences (HEH); University of Pennsylvania (RHH); and Duke University (DBM).
  1. Correspondence
    Dr. Matchar david.matchar{at}duke-nus.edu.sg
View Full Text

Article usage

Article usage: December 2019 to August 2023

AbstractFullPdfSource
Dec 20194301Highwire
Jan 20202400Highwire
Feb 20201600Highwire
Mar 20201702Highwire
Apr 20203402Highwire
May 2020800Highwire
Jun 20201071210Highwire
Jul 202015164Highwire
Aug 20203962Highwire
Sep 20207531Highwire
Oct 20203700Highwire
Nov 20204312Highwire
Dec 20205100Highwire
Jan 20211721Highwire
Feb 20212400Highwire
Mar 20212300Highwire
Apr 20212801Highwire
May 20212130Highwire
Jun 20213100Highwire
Jul 20213011Highwire
Aug 20214500Highwire
Sep 20212000Highwire
Oct 20214110Highwire
Nov 20212800Highwire
Dec 20213000Highwire
Jan 20221300Highwire
Feb 20223100Highwire
Mar 20222001Highwire
Apr 20224000Highwire
May 20221901Highwire
Jun 20222000Highwire
Jul 20221901Highwire
Aug 20223210Highwire
Sep 20226100Highwire
Oct 20222311Highwire
Nov 20226401Highwire
Dec 20223202Highwire
Jan 20234000Highwire
Feb 20231800Highwire
Mar 20231100Highwire
Apr 20231712Highwire
May 20231311Highwire
Jun 20232100Highwire
Jul 20231000Highwire
Aug 2023720Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles